• About
    • About Us
    • Leadership
    • Contact
  • Therapeutics
    • Overview
    • Ropidoxuridine
    • HDAC Inhibitors
  • Diagnostics
    • Overview
    • PSMA-B
    • PC-Rad Test
  • Research & Development
    • Pipeline
    • Clinical Trials
    • Partners and Collaborators
  • Investors
    • Overview
    • Press Releases
    • Governance
    • SEC Filings
    • Stock Info
    • Email Alerts

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

by B2i | Aug 14, 2025 | Press Releases

GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving...

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

by B2i | Jun 24, 2025 | Press Releases

GAITHERSBURG, Md., June 24, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

by B2i | Jun 20, 2025 | Press Releases

GAITHERSBURG, Md., June 20, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

by B2i | Jun 12, 2025 | Press Releases

GAITHERSBURG, Md., June 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

by B2i | Jun 12, 2025 | Press Releases

GAITHERSBURG, Md., June 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

by B2i | Jun 4, 2025 | Press Releases

GAITHERSBURG, Md., June 04, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...
« Older Entries
Next Entries »

Recent Posts

  • Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai’s Drug Discovery Platform Matters More Than Ever
  • Shuttle Pharmaceuticals Acquires AI Health Platform
  • Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00
  • Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
  • Shuttle Executes LOI with Molecule.ai

Recent Comments

No comments to show.

Contact

Shuttle Pharmaceuticals
401 Professional Drive
Suite 260
Gaithersburg, MD 20879

240-430-4212
info@shuttlepharma.com

  • Follow
  • Follow
Sign up for Alerts

Site Links

  • Home
  • Investors
  • Privacy Policy
  • Contact

Our Company

  • About us
  • Leadership
  • Partners and Collaborators

Our Science

  • Therapeutics
  • Diagnostics
  • Pipeline
  • Clinical Trials
© Copyright 2026 Shuttle Pharmaceuticals - All rights reserved
We use cookies to monitor and analyze how our site is used. By using our site, you agree to our use of cookies.